geometrybase
8a0dfd88f0
Request: - Add extracted PDF text generation to the archivist workflow as a standard step. Changes: - Run PDF text extraction automatically for newly archived HKEX PDF sources. - Make the PDF text extractor incremental and manifest-preserving. - Document extracted-text handling in the archivist skill and README. - Mark generated extracted text as no-diff data evidence. - Backfill extracted text for all archived PDF source references. Verification: - Ran git diff --cached --check. - Ran .venv/bin/python -m py_compile scripts/extract_pdf_text.py scripts/archive_hkex_documents.py. - Ran full PDF extraction, then confirmed an incremental rerun skips unchanged files. - Verified 557 PDF source_refs, 557 manifest rows, all status ok, and zero missing text/hash/path issues. Next useful context: - HKEX HTML notices and Yahoo JSON market data remain under data/raw and are not expected in data/extracted_text.
2768 lines
63 KiB
Plaintext
2768 lines
63 KiB
Plaintext
--- page 1 ---
|
||
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those
|
||
defined in the prospectus dated August 12, 2024 (the “Prospectus ”) issued by TYK Medicines, Inc (the “Company ”).
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
|
||
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
|
||
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
|
||
announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
|
||
(including its territories and possessions, any state of the United States and the District of Columbia). This
|
||
announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for
|
||
securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered
|
||
under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act ”) or any states
|
||
securities laws of the United States. The securities may not be offered or sold in the United States except pursuant to
|
||
an effective registration statement or in accordance with an available exemption from, or in a transaction not subject
|
||
to, the registration requirements of the U.S. Securities Act. It is not currently intended for there to be any public offer
|
||
of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore
|
||
transactions in reliance on Regulation S under the U.S. Securities Act.
|
||
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase
|
||
or subscribe for securities. This announcement is not a prospectus. Potential investor to read the Prospectus for
|
||
detailed information about the Global Offering before deciding whether or not to invest in the H Shares.
|
||
TYK Medicines, Inc
|
||
ʮ̡
|
||
(A joint stock company incorporated in the Peo ple’s Republic of China with limited liability)
|
||
(Stock Code: 2410)
|
||
CLARIFICATION ANNOUNCEMENT
|
||
The board of directors of the Company (the “Board”) wishes to revise certain inadvertent cleri cal
|
||
errors in the English and Chinese version of the a nnouncement of final offer price and
|
||
allotment results issued by the Company dated August 19, 2024 (the “Allotment Results
|
||
Announcement ”).
|
||
Please refer to the attached blackline v ersio n of the Allotment Results Announcem ent showing the
|
||
clarifications. Details of th e clarifications are set o ut in t he section headed “Lock-up
|
||
Undertakings ”.
|
||
Save for those clarifications i ndicated in the attac hed d ocument, all other i nformation stated in
|
||
the Allotment Results Announcemen t r emain unchanged and t he Co mpany confirms that the re
|
||
is no material misstatement in the Allotment Results Announc ement.
|
||
By Order of the Board
|
||
TYK Medicines, Inc
|
||
Dr. Wu Yusheng
|
||
Chairman and Executive Director
|
||
Hong Kong, August 23, 2024
|
||
As of the date of this announcement, our Board comprises: (i) Dr. Wu Yusheng and Dr. Jiang
|
||
Mingyu as executive directors; (ii) Dr. Li Jun, Dr. Gu Eric Hong, Dr. Meng Xiaoying, Mr. He
|
||
Chao and Dr. Ding Zhao as non-executive directors; and (iii) Mr. Zhang Senquan, Dr. Leng
|
||
Yuting, Dr. Xu Wenqing and Dr. Shen Xiuhua as independent non-executive directors.
|
||
|
||
|
||
--- page 2 ---
|
||
TYK MEDICINES, INC / 浙江同源康醫藥股份有限公司
|
||
ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT
|
||
RESULTS
|
||
|
||
Unless otherwise defined herein, capitali sed terms used in this announcement shall have the same meanings as
|
||
those defined in the prospectus dated 12 August 2024 (the “Prospectus”) issued by TYK Medicines, Inc (浙江
|
||
同源康醫藥股份有限公司) (the “Company”).
|
||
|
||
Warning: In view of high concentration of shareholding in a small number of H Shareholders, H
|
||
Shareholders and prospective investors should be aware that the price of the H Shares could move
|
||
substantially even with a small number of H Shares traded and should exercise extreme caution when
|
||
dealing in the H Shares.
|
||
SUMMARY
|
||
|
||
Company Information
|
||
Stock code 2410
|
||
Stock short name TYK MEDICINES-B
|
||
Dealings commencement date 20 August 2024*
|
||
|
||
*see note at the end of the announcement
|
||
|
||
Price Information
|
||
Final Offer Price HK$12.100
|
||
Offer Price Range HK$12.100 - HK$12.100
|
||
Offer Price Adjustment exercised No
|
||
|
||
Offer Shares and Share Capital
|
||
Number of Offer Shares 47,880,000
|
||
Number of Offer Shares in Public Offer (after
|
||
reallocation)
|
||
4,788,000
|
||
Number of Offer Shares in International Offer (after
|
||
reallocation)
|
||
43,092,000
|
||
Number of issued shares upon Listing 370,835,818
|
||
|
||
Offer Size Adjustment Option (Upsize option)
|
||
Number of additional shares issued under the option -
|
||
- Public Offer -
|
||
- International Offer -
|
||
|
||
Over-allocation
|
||
No. of Offer Shares over-allocated -
|
||
|
||
Proceeds
|
||
Gross proceeds (Note) HK$ 579.35 million
|
||
Less: Estimated listing expenses payable based
|
||
on Final Offer Price
|
||
HK$ (73.04) million
|
||
Net proceeds HK$ 506.31 million
|
||
|
||
|
||
--- page 3 ---
|
||
Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of
|
||
proceeds, please refer to the Prospectus.
|
||
|
||
ALLOTMENT RESULTS DETAILS
|
||
|
||
HONG KONG PUBLIC OFFERING
|
||
|
||
|
||
No. of valid applications 974
|
||
No. of successful applications 649
|
||
Subscription level 2.29 times
|
||
Re-allocation No
|
||
No. of Offer Shares initially available under the Hong Kong Public
|
||
Offering
|
||
4,788,000
|
||
No. of Offer Shares reallocated from the International Offering 0
|
||
Final no. of Offer Shares under the Public Offer (after
|
||
reallocation)
|
||
4,788,000
|
||
% of Offer Shares under the Hong Kong Public Offering to the
|
||
Global Offering
|
||
10.00%
|
||
|
||
Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to
|
||
www.eipo.com.hk/eIPOAllotment to perform a search by name or identification number or
|
||
www.eipo.com.hk/eIPOAllotment for the full list of allottees.
|
||
INTERNATIONAL OFFERING
|
||
|
||
|
||
No. of placees 116
|
||
Subscription Level 1.01 times
|
||
No. of Offer Shares initially available under the International
|
||
Offering
|
||
43,092,000
|
||
No. of Offer Shares reallocated to the Hong Kong Public Offering 0
|
||
Final no. of Offer Shares under the International Offering (after
|
||
reallocation)
|
||
43,092,000
|
||
% of Offer Shares under the International Offering to the Global
|
||
Offering
|
||
90.00%
|
||
|
||
The Directors confirm that, to the best of their knowledge, information and belief, and save as the waiver and
|
||
consent for Changxing Xingchang (as defined below) as a Cornerstone Investor granted by the Stock Exchange,
|
||
(i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly
|
||
by the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders,
|
||
substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective
|
||
close associates; and (ii) none of the placee s and the public who have purchased the Offer Shares are
|
||
accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the
|
||
Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of
|
||
its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other
|
||
disposition of Shares registered in his/her/its name or otherwise held by him/her/it.
|
||
|
||
|
||
--- page 4 ---
|
||
The placees in the International Offering include the following:
|
||
Cornerstone Investor
|
||
|
||
|
||
|
||
Investor
|
||
No. of
|
||
Offer
|
||
Shares
|
||
allocated
|
||
|
||
|
||
% of Offer
|
||
Shares
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering
|
||
% of total
|
||
issued share
|
||
capital after the
|
||
Global Offering
|
||
Existing
|
||
shareholders or
|
||
their close
|
||
associates
|
||
Changxing
|
||
Xingchang
|
||
Industrial
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership) /
|
||
長興興長產業
|
||
投資合夥企業
|
||
(有限合夥)
|
||
(“Changxing
|
||
Xingchang”)
|
||
17,000,000 35.51% 8.83% 4.58% Yes#
|
||
Total 17,000,000 35.51% 8.83% 4.58%
|
||
|
||
Allottee with waivers/consents obtained
|
||
|
||
|
||
|
||
Investor
|
||
No. of
|
||
shares
|
||
allocated
|
||
|
||
% of offer
|
||
shares
|
||
% of total
|
||
issued H Shares
|
||
after the Global
|
||
Offering
|
||
% of total
|
||
issued share
|
||
capital after the
|
||
Global Offering
|
||
|
||
|
||
Relationship*
|
||
Changxing
|
||
Xingchang
|
||
17,000,000 35.51% 8.83% 4.58% Core connected
|
||
person
|
||
Total 17,000,000 35.51% 8.83% 4.58%
|
||
|
||
# Please refer to the section headed “Others / Additional Information” in this announcement.
|
||
|
||
*The Company has applied for, and the Stock Exchange has granted, a waiver from strict compliance with
|
||
Rules 9.09(b) and 10.04 of the Listing Rules. The allocation of Offer Shares to Changxing Xingchang is in
|
||
compliance with all the conditions under the consent granted by the Stock Exchange. Please refer to the
|
||
“Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the
|
||
Companies (Winding Up and Miscellaneous Provisions) Ordinance” section in the Prospectus for further
|
||
details.
|
||
|
||
|
||
--- page 5 ---
|
||
LOCK-UP UNDERTAKINGS
|
||
Controlling Shareholders
|
||
|
||
|
||
|
||
|
||
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Tetranov
|
||
Pharmaceutical
|
||
(Zhengzhou) Co., Ltd.
|
||
/ 鄭州泰基鴻諾醫藥
|
||
股份有限公司
|
||
(“Tetranov
|
||
Pharmaceutical”) Note
|
||
1
|
||
100,000,000
|
||
(including
|
||
35,000,000
|
||
H Shares and
|
||
65,000,000 Unlisted
|
||
Shares)
|
||
18.17% 26.97% 19 August
|
||
2025 Note 3
|
||
Changxing Liyuan
|
||
Enterprise
|
||
Management
|
||
Partnership
|
||
(Limited Partnership)
|
||
/ 長興利源企業管理
|
||
合夥企業(有限
|
||
合夥) (“Changxing
|
||
Liyuan”) Note 2
|
||
22,670,000
|
||
(including
|
||
7,934,500 H Shares
|
||
and 14,735,500
|
||
Unlisted
|
||
Shares)
|
||
4.12% 6.11% 19 August
|
||
2025 Note 3
|
||
Changxing Gangyuan
|
||
Enterprise
|
||
Management
|
||
Partnership (Limited
|
||
Partnership) / 長興罡
|
||
源企業管理合
|
||
夥企業(有限合夥)
|
||
(“Changxing
|
||
Gangyuan”) Note 2
|
||
4,800,000
|
||
(including
|
||
1,680,000 H
|
||
Shares and
|
||
3,120,000 Unlisted
|
||
Shares)
|
||
0.87% 1.29% 19 August
|
||
2025 Note 3
|
||
|
||
|
||
--- page 6 ---
|
||
Changxing Caiyuan
|
||
Enterprise
|
||
Management
|
||
Partnership
|
||
(Limited Partnership) /
|
||
長興彩源企業管理合
|
||
夥企業(有限
|
||
合夥) (“Changxing
|
||
Caiyuan”) Note 2
|
||
3,780,000
|
||
(including
|
||
1,323,000 (H
|
||
Shares and
|
||
2,457,000 Unlisted
|
||
Shares)
|
||
0.69% 1.02% 19 August
|
||
2025 Note 3
|
||
Subtotal 131,250,000 23.85% 35.39%
|
||
Notes:
|
||
|
||
(1) Tetranov Pharmaceutical beneficially owns 35,000,000 H Shares and 65,000,000 Unlisted Shares.
|
||
Tetranov Pharmaceutical is held as to approximately 30.66% by Dr. Wu, approximately 20.15% by
|
||
Zhengzhou Hongnuo and approximately 3.02% by Zhengzhou Derui, respectively. Zhengzhou
|
||
Hongnuo is managed by its executive partner, Huzhou Derui, which is owned as to 38.75% by Dr.
|
||
Wu, 61% by Zhengzhou Derui and 0.25% by Mr. ZHANG Sen (張森), one of the Group’s employees.
|
||
Zhengzhou Derui is wholly owned by Dr. Wu. As such, under the SFO, Dr. Wu is deemed to be
|
||
interested in the 35,000,000 H Shares and 65,000,000 Unlisted Shares held by Tetranov
|
||
Pharmaceutical. Ms. Zhu is spouse of Dr. Wu. Therefore, under the SFO, Ms. Zhu is deemed to be
|
||
interested in the same number of Shares in which Dr. Wu is interested in.
|
||
|
||
(2) Changxing Liyuan beneficially owns 7,934,500 H Shares and 14,735,500 Unlisted Shares.
|
||
Changxing Liyuan is managed by its executive partner, Zhengzhou Derui, which is wholly owned by
|
||
Dr. Wu.
|
||
|
||
Each of Changxing Caiyuan and Changxing Gangyuan is the ESOP Platform. Changxing Caiyuan
|
||
beneficially owns 1,323,000 H Shares and 2,457,000 Unlisted Shares. Changxing Gangyuan
|
||
beneficially owns 1,680,000 H Shares and 3,120,000 Unlisted Shares. Each of Changxing Caiyuan
|
||
and Changxing Gangyuan is managed by its executive partner, Huzhou Derui, which is owned as to
|
||
38.75% by Dr. Wu, 61% by Zhengzhou Derui and 0.25% by Mr. ZHANG Sen ( 張森), one of the
|
||
Group’s employees. Zhengzhou Derui is wholly owned by Dr. Wu.
|
||
|
||
As such, under the SFO, Dr. Wu is deemed to be interested in (i) the 7,934,500 H Shares and
|
||
14,735,500 Unlisted Shares held by Changxing Liyuan; (ii) the 1,323,000 H Shares and 2,457,000
|
||
Unlisted Shares held by Changxing Caiyuan; and (iii) the 1,680,000 H Shares and 3,120,000
|
||
Unlisted Shares held by Changxing Gangyuan.
|
||
|
||
(3) The expiry date of the lock -up period shown in the table above is pursuant to the Hong Kong
|
||
Underwriting Agreement and the applicable PRC laws.
|
||
|
||
|
||
--- page 7 ---
|
||
Pre-IPO Investors (as defined in the “History , Development and Corporate Structure” section of the
|
||
Prospectus)
|
||
|
||
|
||
|
||
|
||
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Ningbo Meishan
|
||
Bonded Port Area
|
||
Houji Tongnuo
|
||
Investment
|
||
Management
|
||
Partnership (Limited
|
||
Partnership) / 寧波梅
|
||
山保稅港區厚紀通諾
|
||
投資管理合夥企業(有
|
||
限合夥) (Houji
|
||
Tongnuo) Note 1
|
||
14,146,619
|
||
(including
|
||
4,951,317 H
|
||
Shares and
|
||
9,195,302 Unlisted
|
||
Shares)
|
||
2.57% 3.81% 19 August
|
||
2025 Note 7
|
||
Changsanjiao
|
||
Tengyuan (Changxing)
|
||
Medical Equity
|
||
Investment Partnership
|
||
(Limited Partnership) /
|
||
長三角騰遠(長興)醫
|
||
療股權投資合夥企業(
|
||
有限合夥)
|
||
(Changsanjiao
|
||
Tengyuan)
|
||
12,600,000
|
||
(including
|
||
4,410,000 H
|
||
Shares and
|
||
8,190,000 Unlisted
|
||
Shares)
|
||
2.29% 3.40% 19 August
|
||
2025 Note 7
|
||
Changxing Guohai
|
||
Donghu Equity
|
||
Investment Partnership
|
||
(Limited Partnership) /
|
||
長興國海東湖股權投
|
||
資合夥企業(有限合夥
|
||
) (Changxing
|
||
Guohai) Notes 2 & 6
|
||
12,185,600
|
||
(including
|
||
3,046,400 H
|
||
Shares and
|
||
9,139,200 Unlisted
|
||
Shares)
|
||
1.58% 3.29% 19 August
|
||
2025 Note 7
|
||
Sichuan Huiyu
|
||
Pharmaceutical Co.,
|
||
Ltd. / 四川匯宇製藥
|
||
股份有限公司 (Huiyu
|
||
Pharmaceutical)
|
||
10,468,584
|
||
(including
|
||
3,664,004 H
|
||
Shares and
|
||
6,804,580 Unlisted
|
||
Shares)
|
||
1.90% 2.82% 19 August
|
||
2025 Note 7
|
||
Changxing Xingyin
|
||
Equity Investment
|
||
Partnership (Limited
|
||
Partnership) / 長興興
|
||
銀股權投資合夥企業(
|
||
有限合夥) (Changxing
|
||
Xingyin) Notes 3 & 6
|
||
10,015,305
|
||
(including
|
||
3,505,357 H
|
||
Shares and
|
||
6,509,948 Unlisted
|
||
Shares)
|
||
1.82% 2.70% 19 August
|
||
2025 Note 7
|
||
|
||
|
||
--- page 8 ---
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Jiangsu Addor Capital
|
||
Results Innovation
|
||
Venture Capital Fund
|
||
(Limited Partnership) /
|
||
江蘇毅達成果創新創
|
||
業投資基金(有限合夥
|
||
) (Addor Results) Note 4
|
||
9,600,000 (H
|
||
Shares)
|
||
4.98% 2.59% 19 August
|
||
2025 Note 7
|
||
Chengdu Boyuan Jiayu
|
||
Venture Capital
|
||
Partnership (Limited
|
||
Partnership) / 成都博
|
||
遠嘉昱創業投資合夥
|
||
企業(有限合夥)
|
||
(Chengdu Boyuan)
|
||
9,201,568
|
||
(including
|
||
3,220,549 H
|
||
Shares and
|
||
5,981,019 Unlisted
|
||
Shares)
|
||
1.67% 2.48% 19 August
|
||
2025 Note 7
|
||
Jiangsu Small and
|
||
Medium Enterprises
|
||
Development Fund
|
||
(Limited Partnership) /
|
||
江蘇中小企業發展基
|
||
金(有限合夥) (Jiangsu
|
||
SME) Note 4
|
||
7,200,000 (H
|
||
Shares)
|
||
3.74% 1.94% 19 August
|
||
2025 Note 7
|
||
Kunshan
|
||
Huachuang Yida
|
||
Biomedical Equity
|
||
Investment
|
||
Enterprise (Limited
|
||
Partnership) / 昆山
|
||
華創毅達生醫股權
|
||
投資企業(有限合
|
||
夥) (Huachuang
|
||
Yida)
|
||
7,200,000 (H
|
||
Shares)
|
||
3.74% 1.94% 19 August
|
||
2025 Note 7
|
||
Hangzhou Sanhua
|
||
Hongdao Venture
|
||
Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership) / 杭
|
||
州三花弘道創業
|
||
投資合夥企業(
|
||
有限合夥)
|
||
(Sanhua
|
||
Hongdao)
|
||
7,200,000 (H
|
||
Shares)
|
||
3.74% 1.94% 19 August
|
||
2025 Note 7
|
||
|
||
|
||
--- page 9 ---
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Xiamen Ronghui
|
||
Hongshang Equity
|
||
Investment
|
||
Partnership (Limited
|
||
Partnership) / 廈門融
|
||
匯弘上股權投資合
|
||
夥企業(有限合夥)
|
||
(Ronghui
|
||
Hongshang)
|
||
7,200,000
|
||
(including
|
||
2,520,000 H
|
||
Shares and
|
||
4,680,000 Unlisted
|
||
Shares)
|
||
1.31% 1.94% 19 August
|
||
2025 Note 7
|
||
Ningbo Fuqi Venture
|
||
Capital Partnership
|
||
(Limited Partnership) /
|
||
寧波複祺創業投資合
|
||
夥企業(有限合夥)
|
||
(Fuqi Investment) Note 6
|
||
7,200,000
|
||
(including
|
||
2,520,000 H
|
||
Shares and
|
||
4,680,000 Unlisted
|
||
Shares)
|
||
1.31% 1.94% 19 August
|
||
2025 Note 7
|
||
Shenzhen Yangzi
|
||
Xinkang
|
||
Pharmaceutical
|
||
Investment Enterprise
|
||
(Limited Partnership) /
|
||
深圳揚子鑫康醫藥投
|
||
資企業(有限合夥)
|
||
(Yangzi Xinkang)
|
||
6,259,566
|
||
(including
|
||
2,190,848 H
|
||
Shares and
|
||
4,068,17718
|
||
Unlisted Shares)
|
||
1.14% 1.69% 19 August
|
||
2025 Note 7
|
||
Zhuzhou Guohai
|
||
Guochuang Qianjin
|
||
Pharmaceutical
|
||
Venture Capital
|
||
Partnership (Limited
|
||
Partnership) / 株洲市
|
||
國海國創千金醫藥創
|
||
業投資合夥企業(有限
|
||
合夥) (Guohai
|
||
Guochuang) Note 2
|
||
6,144,000
|
||
(including
|
||
1,536,000 H
|
||
Shares and
|
||
4,608,000 Unlisted
|
||
Shares)
|
||
0.80% 1.66% 19 August
|
||
2025 Note 7
|
||
Zhuzhou Guochuang
|
||
Junhe Investment
|
||
Partnership (Limited
|
||
Partnership) / 株洲市
|
||
國創君和投資合夥企
|
||
業(有限合夥)
|
||
(Guochuang Junhe)
|
||
Note 5
|
||
5,400,000
|
||
(including
|
||
1,890,000 H
|
||
Shares and
|
||
3,510,000 Unlisted
|
||
Shares)
|
||
0.98% 1.46% 19 August
|
||
2025 Note 7
|
||
|
||
|
||
--- page 10 ---
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Ningbo Meishan
|
||
Bonded Port Area
|
||
Houyang Tongchi
|
||
Investment
|
||
Management
|
||
Partnership (Limited
|
||
Partnership) / 寧波梅
|
||
山保稅港區厚揚通馳
|
||
投資管理合夥企業(有
|
||
限合夥) (Houyang
|
||
Tongchi) Note 1
|
||
5,258,035
|
||
(including
|
||
1,840,312 H
|
||
Shares and
|
||
3,417,723 Unlisted
|
||
Shares)
|
||
0.96% 1.42% 19 August
|
||
2025 Note 7
|
||
Huzhou Zhongjin Qihe
|
||
Equity Investment
|
||
Partnership (Limited
|
||
Partnership) / 湖州中
|
||
金啟合股權投資合夥
|
||
企業(有限合夥)
|
||
(CICC Qihe) Note 6
|
||
5,234,292 (H
|
||
Shares)
|
||
2.72% 1.41% 19 August
|
||
2025 Note 7
|
||
Zhuzhou Wenzhou
|
||
Junzhe Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
/ 株洲市文周君喆創
|
||
業投資合夥企業(有
|
||
限合夥) (Wenzhou
|
||
Junzhe) Note 5
|
||
5,120,000
|
||
(including
|
||
1,792,000 H
|
||
Shares and
|
||
3,328,000 Unlisted
|
||
Shares)
|
||
0.93% 1.38% 19 August
|
||
2025 Note 7
|
||
Zhejiang Silk Road
|
||
Industrial Investment
|
||
Fund Partnership
|
||
(Limited Partnership)
|
||
/ 浙江絲路產業投資
|
||
基金合夥企業(有限
|
||
合夥) (Zhejiang Silk
|
||
Road)
|
||
5,007,653 (H
|
||
Shares)
|
||
2.60% 1.35% 19 August
|
||
2025 Note 7
|
||
Hunan Xiangyi
|
||
Investment Tongyuan
|
||
No. 1 Venture Capital
|
||
Partnership (Limited
|
||
Partnership) / 湖南湘
|
||
醫投同源壹號創業
|
||
投資合夥企業(有限
|
||
合夥) (Hunan
|
||
Xiangyi)
|
||
4,761,905
|
||
(including
|
||
1,666,667 H
|
||
Shares and
|
||
3,095,238 Unlisted
|
||
Shares)
|
||
0.87% 1.28% 19 August
|
||
2025 Note 7
|
||
|
||
|
||
--- page 11 ---
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Hangzhou Qizhen
|
||
Future Innovation
|
||
Equity Investment
|
||
Partnership (Limited
|
||
Partnership) / 杭州啟
|
||
真未來創新股權投
|
||
資合夥企業(有限合
|
||
夥) (Hangzhou
|
||
Qizhen)
|
||
4,096,000 (H
|
||
Shares)
|
||
2.13% 1.10% 19 August
|
||
2025 Note 7
|
||
Yangzhou Zekang
|
||
Equity Investment
|
||
Partnership (Limited
|
||
Partnership) / 揚州澤
|
||
康股權投資合夥企
|
||
業(有限合夥)
|
||
(Yangzhou Zekang)
|
||
3,655,575
|
||
(including
|
||
1,279,451 H
|
||
Shares and
|
||
2,376,124 Unlisted
|
||
Shares)
|
||
0.66% 0.99% 19 August
|
||
2025 Note 7
|
||
Jiangsu Talent
|
||
Innovation Venture
|
||
Capital Fund IV
|
||
(Limited Partnership)
|
||
/ 江蘇人才創新創業
|
||
投資四期基金(有限
|
||
合夥) (Jiangsu
|
||
Talent) Note 4
|
||
3,600,000 (H
|
||
Shares)
|
||
1.87% 0.97% 19 August
|
||
2025 Note 7
|
||
Changxing Xinsheng
|
||
Equity Investment
|
||
Partnership (Limited
|
||
Partnership) / 長興鑫
|
||
晟股權投資合夥企
|
||
業(有限合夥)
|
||
(Changxing
|
||
Xinsheng) Notes 3 & 6
|
||
3,140,575
|
||
(including
|
||
1,099,201 H
|
||
Shares and
|
||
2,041,374 Unlisted
|
||
Shares)
|
||
0.57% 0.85% 19 August
|
||
2025 Note 7
|
||
Huzhou Haibang
|
||
Shuhu Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
/ 湖州海邦數湖創業
|
||
投資合夥企業(有限
|
||
合夥) (Haibang
|
||
Shuhu) Note 6
|
||
3,072,000
|
||
(including
|
||
1,075,200 H
|
||
Shares and
|
||
1,996,800 Unlisted
|
||
Shares)
|
||
0.56% 0.83% 19 August
|
||
2025 Note 7
|
||
|
||
|
||
--- page 12 ---
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Jiaxing Xingren
|
||
Equity Investment
|
||
Partnership (Limited
|
||
Partnership) / 嘉興行
|
||
仁股權投資合夥企
|
||
業(有限合夥)
|
||
(Jiaxing Xingren)
|
||
2,380,952
|
||
(including 833,333
|
||
H
|
||
Shares and
|
||
1,547,619 Unlisted
|
||
Shares)
|
||
0.43% 0.64% 19 August
|
||
2025 Note 7
|
||
Mr. JI Aining / 吉愛
|
||
寧
|
||
2,380,000
|
||
(including 833,000
|
||
H
|
||
Shares and
|
||
1,547,000 Unlisted
|
||
Shares)
|
||
0.43% 0.64% 19 August
|
||
2025 Note 7
|
||
Jiaxing Wangying
|
||
Shanghe Equity
|
||
Investment
|
||
Partnership (Limited
|
||
Partnership) / 嘉興望
|
||
盈上和股權投資合
|
||
夥企業(有限合夥)
|
||
(Wangying Shanghe)
|
||
Note 6
|
||
1,884,160 (H
|
||
Shares)
|
||
0.98% 0.51% 19 August
|
||
2025 Note 7
|
||
Shanghai Kaicheng
|
||
Enterprise
|
||
Management
|
||
Consulting
|
||
Partnership (Limited
|
||
Partnership) / 上海凱
|
||
乘企業管理諮詢合
|
||
夥企業(有限合夥)
|
||
(Shanghai Kaicheng)
|
||
720,000 (including
|
||
252,000 H
|
||
Shares and 468,000
|
||
Unlisted Shares)
|
||
0.13% 0.19% 19 August
|
||
2025 Note 7
|
||
Shanghai Fanxi
|
||
Enterprise
|
||
Management
|
||
Partnership (Limited
|
||
Partnership) / 上海凡
|
||
熹企業管理合夥企
|
||
業(有限合夥)
|
||
(Shanghai Fanxi) Note
|
||
5
|
||
600,000 (including
|
||
210,000 H
|
||
Shares and 390,000
|
||
Unlisted Shares)
|
||
0.11% 0.16% 19 August
|
||
2025 Note 7
|
||
Huzhou Talent
|
||
Innovation Equity
|
||
Investment Fund
|
||
523,429 (H
|
||
Shares)
|
||
0.27% 0.14% 19 August
|
||
2025 Note 7
|
||
|
||
|
||
--- page 13 ---
|
||
Name
|
||
Number of shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Partnership (Limited
|
||
Partnership) / 湖州市
|
||
人才創新股權投資
|
||
基金合夥企業(有限
|
||
合夥) (Huzhou
|
||
Talent) Note 6
|
||
Subtotal 183,455,818 49.79% 49.47%
|
||
Notes:
|
||
|
||
(1) Houji Tongnuo and Houyang Tongchi in aggregate will hold 19,404,654 Shares which represent
|
||
approximately 5.23% of the total issued share capital of the Company upon Listing.
|
||
|
||
(2) Changxing Guohai and Guohai Guochuang in aggregate will hold 18,329,600 Shares which
|
||
represent approximately 4.94% of the total issued share capital of the Company upon Listing.
|
||
|
||
(3) Changxing Xingyin and Changxing Xinsheng in aggregate will hold 13,155,880 Shares
|
||
approximately 3.55% of the total issued share capital of the Company upon Listing.
|
||
|
||
(4) Addor Results, Jiangsu SME and Jiangsu Talent in aggregate will hold 20,400,000 Shares which
|
||
represent approximately 5.50% of the total issued share capital of the Company upon Listing.
|
||
|
||
(5) Guochuang Junhe, Wenzhou Junzhe and Shanghai Fanxi in aggregate will hold 11,120,000 Shares
|
||
which represent approximately 3.00% of the total issued share capital of the Company upon Listing.
|
||
|
||
(6) More than 30% of the partnership interest of the relevant Shareholder is ultimately under the
|
||
supervision and management of Zhejiang Provincial People’s Government. Such relevant
|
||
Shareholders under the supervision and management of Zhejiang Provincial Peop le’s Government
|
||
will in aggregate hold 43,255,361 Shares which represent approximately 11.66% of the total issued
|
||
share capital of the Company upon Listing, without taking into account the Shares to be subscribed
|
||
by the cornerstone investor that is also ultimately under the supervision and management of Zhejiang
|
||
Provincial People’s Government, as further described in the section headed “Cornerstone Placing”
|
||
in the Prospectus.
|
||
|
||
(7) The expiry date of the lock -up period shown in the table above is pursuant to the applicable PRC
|
||
laws.
|
||
|
||
|
||
--- page 14 ---
|
||
Existing Shareholder (other than the Pre-IPO Investors as defined in the “History, Development and
|
||
Corporate Structure” section of the Prospectus)
|
||
|
||
|
||
|
||
|
||
|
||
Name
|
||
Number of
|
||
shares held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings
|
||
upon Listing
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Pivot Pharma Tech
|
||
(Shanghai) Co., Ltd. /
|
||
貝沃特醫藥技術(上
|
||
海)有限公司 (Pivot
|
||
Pharma)
|
||
8,250,000
|
||
(including
|
||
2,887,500 H
|
||
Shares and
|
||
5,362,500 Unlisted
|
||
Shares)
|
||
1.50% 2.22% 19 August
|
||
2025
|
||
Subtotal 8,250,000 1.50% 2.22%
|
||
The expiry date of the lock-up period shown in the table above is pursuant to the applicable PRC laws.
|
||
|
||
Cornerstone Investor
|
||
|
||
|
||
|
||
|
||
|
||
Name
|
||
Number of
|
||
shares held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total issued H
|
||
Shares after the
|
||
Global Offering
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
|
||
Last day
|
||
subject to the
|
||
lock-up
|
||
undertakings
|
||
Changxing
|
||
Xingchang
|
||
17,000,000 (H
|
||
Shares)
|
||
8.83% 4.58% 19 February
|
||
2025
|
||
Subtotal 17,000,000 8.83% 4.58%
|
||
The Cornerstone Investor shall not dispose of any of the Offer Shares subscribed pursuant to the
|
||
cornerstone investment agreement on or before the indicated date.
|
||
|
||
|
||
--- page 15 ---
|
||
PLACEE CONCENTRATION ANALYSIS
|
||
|
||
|
||
|
||
|
||
|
||
|
||
Placees(1)
|
||
|
||
|
||
|
||
Number of H
|
||
Shares
|
||
allotted
|
||
|
||
|
||
|
||
|
||
Allotment as % of
|
||
International Offering
|
||
|
||
|
||
|
||
|
||
Allotment as % of total
|
||
Offer Shares
|
||
|
||
|
||
|
||
Numb
|
||
er of Shares
|
||
held upon
|
||
Listing(2)
|
||
|
||
|
||
|
||
|
||
% of total issued share
|
||
capital upon Listing
|
||
Top 1 17,000,000 39.45% 35.51% 60,255,361 16.25%
|
||
Top 5 34,103,500 79.14% 71.23% 77,358,861 20.86%
|
||
Top 10 41,036,500 95.23% 85.71% 84,291,861 22.73%
|
||
Top 25 43,046,500 99.89% 89.90% 86,301,861 23.27%
|
||
|
||
Notes:
|
||
(1) Ranking of placees is based on the number of H Shares allotted to the placees.
|
||
(2) Number of Shares held upon Listing includes existing Shares.
|
||
|
||
|
||
--- page 16 ---
|
||
H SHAREHOLDERS CONCENTRATION ANALYSIS
|
||
|
||
|
||
|
||
|
||
|
||
H Shareholders(1)
|
||
|
||
|
||
Number of H
|
||
Shares allotted
|
||
|
||
|
||
Allotment
|
||
as % of
|
||
International
|
||
Offering
|
||
|
||
|
||
Allotment as % of
|
||
total Offer
|
||
Shares
|
||
|
||
|
||
Number of H Shares
|
||
held upon
|
||
Listing
|
||
|
||
|
||
% of total issued H
|
||
Shares capital
|
||
upon Listing
|
||
|
||
Number of Shares
|
||
held upon
|
||
Listing(2)
|
||
Top 1 0 0.00% 0.00% 45,937,500 23.85% 131,250,000
|
||
Top 5 17,000,000 39.45% 35.51% 116,625,539 60.56% 226,305,361
|
||
Top 10 29,113,500 67.56% 60.81% 144,948,321 75.26% 275,431,168
|
||
Top 25 39,406,500 91.45% 82.30% 182,194,340 94.60% 356,881,366
|
||
|
||
Notes:
|
||
(1) Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.
|
||
(2) Number of Shares held upon Listing includes existing Shares.
|
||
|
||
|
||
--- page 17 ---
|
||
SHAREHOLDER CONCENTRATION ANALYSIS
|
||
|
||
|
||
|
||
|
||
|
||
Shareholders(1)
|
||
|
||
|
||
|
||
Number of H
|
||
Shares allotted
|
||
|
||
|
||
|
||
Allotment as % of
|
||
International
|
||
Offering
|
||
|
||
|
||
|
||
|
||
Allotment as % of total
|
||
Offer Shares
|
||
|
||
|
||
|
||
|
||
Number of Shares held
|
||
upon Listing(2)
|
||
|
||
|
||
|
||
% of total issued share
|
||
capital upon
|
||
Listing
|
||
Top 1 0 0.00% 0.00% 131,250,000 35.39%
|
||
Top 5 17,000,000 39.45% 35.51% 243,910,015 65.77%
|
||
Top 10 17,000,000 39.45% 35.51% 290,150,167 78.24%
|
||
Top 25 36,543,500 84.80% 76.32% 358,779,318 96.75%
|
||
|
||
Notes:
|
||
(1) Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.
|
||
(2) Number of Shares held upon Listing includes existing Shares.
|
||
|
||
|
||
--- page 18 ---
|
||
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
|
||
Subject to the satisfaction of the conditions set out in the Prospectus, 974 valid applications made by
|
||
the public will be conditionally allocated on the basis set out below:
|
||
Pool A:
|
||
|
||
NO. OF H SHARES
|
||
APPLIED
|
||
FOR
|
||
|
||
NO. OF
|
||
VALID
|
||
APPLICAT
|
||
IONS
|
||
|
||
|
||
BASIS OF
|
||
ALLOTMENT/BALLOT
|
||
APPROXI
|
||
MATE
|
||
PERCENTAGE
|
||
ALLOTTED OF
|
||
THE TOTAL NO. OF
|
||
H SHARES
|
||
APPLIED FOR
|
||
|
||
500 614 294 out of 614 to receive 500
|
||
Shares 47.88%
|
||
1,000
|
||
117 112 out of 117 to receive 500
|
||
Shares 47.86%
|
||
1,500 37 500 Shares plus 16 out of 37 to
|
||
receive additional 500 Shares 47.75%
|
||
2,000 36 500 Shares plus 32 out of 36 to
|
||
receive additional 500 Shares 47.22%
|
||
2,500 18 1,000 Shares plus 6 out of 18 to
|
||
receive additional 500 Shares 46.67%
|
||
3,000 19 1,000 Shares plus 15 out of 19 to
|
||
receive additional 500 Shares 46.49%
|
||
3,500 8 1,500 Shares plus 2 out of 8 to
|
||
receive additional 500 Shares 46.43%
|
||
4,000 20 1,500 Shares plus 14 out of 20 to
|
||
receive additional 500 Shares 46.25%
|
||
4,500 1 2,000 Shares 44.44%
|
||
5,000 23 2,000 Shares plus 10 out of 23 to
|
||
receive additional 500 Shares 44.35%
|
||
6,000 5 2,500 Shares plus 1 out of 5 to
|
||
receive additional 500 Shares 43.33%
|
||
7,000
|
||
2 3,000 Shares 42.86%
|
||
|
||
8,000
|
||
|
||
7 3,000 Shares plus 5 out of 7 to
|
||
receive additional 500 Shares 41.96%
|
||
9,000
|
||
7 3,500 Shares plus 2 out of 7 to
|
||
receive additional 500 Shares 40.48%
|
||
10,000
|
||
18 4,000 Shares 40.00%
|
||
|
||
|
||
--- page 19 ---
|
||
NO. OF H SHARES
|
||
APPLIED
|
||
FOR
|
||
|
||
NO. OF
|
||
VALID
|
||
APPLICAT
|
||
IONS
|
||
|
||
|
||
BASIS OF
|
||
ALLOTMENT/BALLOT
|
||
APPROXI
|
||
MATE
|
||
PERCENTAGE
|
||
ALLOTTED OF
|
||
THE TOTAL NO. OF
|
||
H SHARES
|
||
APPLIED FOR
|
||
15,000 3 6,000 Shares 40.00%
|
||
20,000
|
||
5 8,000 Shares 40.00%
|
||
25,000
|
||
3 10,000 Shares 40.00%
|
||
30,000
|
||
3 12,000 Shares 40.00%
|
||
50,000
|
||
3 20,000 Shares 40.00%
|
||
60,000
|
||
1 24,000 Shares 40.00%
|
||
70,000
|
||
1 28,000 Shares 40.00%
|
||
80,000
|
||
1 31,500 Shares 39.38%
|
||
90,000 1 35,000 Shares 38.89%
|
||
100,000
|
||
5 38,500 Shares 38.50%
|
||
200,000
|
||
4 76,500 Shares plus 3 out of 4 to
|
||
receive additional 500 Shares 38.44%
|
||
300,000
|
||
5 115,000 Shares plus 3 out of 5 to
|
||
receive additional 500 Shares 38.43%
|
||
400,000
|
||
3 153,500 Shares plus 1 out of 3 to
|
||
receive additional 500 Shares 38.42%
|
||
Total 970 Total number of Pool A
|
||
successful applicants: 645
|
||
|
||
|
||
--- page 20 ---
|
||
Pool B
|
||
|
||
NO. OF H SHARES
|
||
APPLIED
|
||
FOR
|
||
|
||
NO. OF
|
||
VALID
|
||
APPLICAT
|
||
IONS
|
||
|
||
|
||
BASIS OF
|
||
ALLOTMENT/BALLOT
|
||
APPROXI
|
||
MATE
|
||
PERCENTAGE
|
||
ALLOTTED OF THE
|
||
TOTAL NO. OF H
|
||
SHARES APPLIED
|
||
FOR
|
||
500,000 1 240,000 Shares 48.00%
|
||
1,250,000 1 598,500 Shares 47.88%
|
||
1,500,000 1 718,000 Shares 47.87%
|
||
1,750,000 1 837,500 Shares 47.86%
|
||
Total 4 Total number of Pool B
|
||
successful applicants: 4
|
||
|
||
|
||
As of the date of this announcement, the relevant subscription monies previously deposited in the
|
||
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
|
||
Investors should contact their relevant brokers for any inquiries.
|
||
|
||
COMPLIANCE WITH LISTING RULES AND GUIDANCE
|
||
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of
|
||
which consent has been obtained, the Company has complied with the Listing Rules and guidance
|
||
materials in relation to the placing, allotment and listing of the H Shares.
|
||
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the
|
||
public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by
|
||
them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC
|
||
transaction levy and trading fee payable.
|
||
|
||
OTHERS / ADDITIONAL INFORMATION
|
||
|
||
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the
|
||
Company, a waiver and consent under Rule 9.09(b) and Rule 10.04 of the Listing Rules and Paragraph
|
||
5(2) of the Placing Guidelines allow Changxing Xingchang to subscribe for H Shares as Cornerstone
|
||
Investor in the Global Offering. As more than 30% of the partnership interest of each of Huzhou
|
||
Talent, Changxing Xingyin, Changxing Xinsheng, CICC Qihe, Changxing Guohai, Haibang Shuhu,
|
||
Wangying Shanghe and Fuqi Investmen t (the existing Shareholders, collectively, the “ Zhejiang-
|
||
related Entities ”) are ultimately under the supervision and management of Zhejiang Provincial
|
||
People’s Government, and the Zhejiang -related Entities will in aggregate hold 43,255,361 Shares
|
||
which represent approximately 11.66% of the total issued share capital of the Company upon Listing,
|
||
they are regarded as core connected persons of the Company. Changxing Xingchang is an entity under
|
||
the supervision and management of Changxing County People’s Gover nment which is a county
|
||
government in Zhejiang province. For the details, please refer to the section headed “Waivers from
|
||
Strict Compliance with Listing Rules and Exemption from Strict Compliance with the Companies
|
||
(Winding Up and Miscellaneous Provisions) Ordinance – Cornerstone Subscription by Core
|
||
Connected Person During the Listing Application Process”.
|
||
|
||
|
||
--- page 21 ---
|
||
DISCLAIMERS
|
||
|
||
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock
|
||
Exchange”) and Hong Kong Securities Clearing Company Limited (“ HKSCC”) take no
|
||
responsibility for the contents of this announcement, make no representation as to its accuracy or
|
||
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or
|
||
in reliance upon the whole or any part of the contents of this announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into the
|
||
United States (including its territories and possessions, any state of the United States and the District
|
||
of Columbia). This announcement does not const itute or form a part of any offer or solicitation to
|
||
purchase or subscribe for securities in the United States. The securities mentioned herein have not
|
||
been, and will not be, registered under the United States Securities Act of 1933, as
|
||
amended (the “U.S. Securities Act ”). The securities may not be offered or sold in the United States
|
||
except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in
|
||
compliance with any applicable state securities laws, or outside the United States unless in compliance
|
||
with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United
|
||
States.
|
||
The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance
|
||
on Regulation S under the U.S. Securities Act.
|
||
This announcement is for information purposes only and does not constitute an invitation or offer to
|
||
acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential
|
||
investors should read the Prospectus dated 12 August 2024 issued by TYK Medicines, Inc for detailed
|
||
information about the Global Offering described below before deciding whether or not to invest in the
|
||
Shares thereby being offered.
|
||
Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and
|
||
on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the
|
||
Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events
|
||
set out in the paragraph headed “Underwriting – 2. Underwriting Arrangements and Expenses –Hong
|
||
Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m.
|
||
(Hong Kong time) on the Listing Date (which is currently expected to be on 20 August 2024).
|
||
|
||
PUBLIC FLOAT
|
||
Immediately following completion of the Global Offering, (i) taking into account the Conversion of
|
||
144,706,173 Unlisted Shares into H Shares to be issued and held by the Pre-IPO Investors and existing
|
||
Shareholders, 93,007,501 H Shares, representing 25.08% of the total issued Shares will be held in the
|
||
public hands, satisfying the minimum percentage requirement under Rule 8.08(1) of the Listing Rules;
|
||
(ii) the three largest public Shareholders will not hold more than 50% of the Shares held in the public
|
||
hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iii)
|
||
there will be at least 300 Shareholders at the ti me of Listing in compliance with Rule 8.08(2) of the
|
||
Listing Rules.
|
||
The Directors confirm that immediately after the completion of the Global Offering, (i) no placee will,
|
||
individually, be placed more than 10% of the enlarged issued share capital of the Company; and (ii)
|
||
there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company.
|
||
|
||
|
||
--- page 22 ---
|
||
COMMENCEMENT OF DEALINGS
|
||
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, 20 August
|
||
2024 (Hong Kong time), provided that the Global Offering has become unconditional and the right of
|
||
termination described in “Underwriting — 2. Underwriting Arrangements and Expenses — Hong
|
||
Kong Public Offering — Grounds for Termination” has not been exercised. Investors who trade the H
|
||
Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates
|
||
or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.
|
||
|
||
Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. on
|
||
Tuesday, 20 August 2024 (Hong Kong time), it is expected that dealings in the H Shares on the Stock
|
||
Exchange will commence at 9:00 a.m. on Tuesday, 20 August 2024 (Hong Kong time). The H Shares
|
||
will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 2410.
|
||
|
||
By order of the Board
|
||
TYK Medicines, Inc
|
||
(浙江同源康醫藥股份有限公司)
|
||
Dr. WU Yusheng
|
||
Chairman of the Board, Executive Director and
|
||
Chief Executive Officer
|
||
|
||
|
||
Hong Kong, 19 August 2024
|
||
|
||
As of the date of this announcement, the executive Directors are Dr. WU Yusheng and Dr. JIANG
|
||
Mingyu, the non-executive Directors are Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE
|
||
Chao and Dr. DING Zhao, and the independent non -executive Directors are Mr. ZHANG Senquan,
|
||
Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua.
|
||
|
||
|
||
--- page 23 ---
|
||
TYK MEDICINES, INC / 浙江同源康醫藥股份有限公司
|
||
最終發售價及配發結果公告
|
||
|
||
除本公告另有界定者外，本公告所用詞彙與 浙江同源康醫藥股份有限公司 （「本公司」）所刊發日期
|
||
為2024年8月12日的招股章程（「招股章程」）所界定者具有相同涵義。
|
||
|
||
警告:鑒於股權高度集中於數目不多之 H 股股東，即使少量 H 股成交，該公司之 H 股價格亦可能
|
||
大幅波動，H 股股東及有意投資者於買賣該公司 H 股時務請審慎行事。
|
||
|
||
摘要
|
||
|
||
公司資料
|
||
股份代號 2410
|
||
股份簡稱 同源康醫藥-B
|
||
開始買賣日期 2024 年 8 月 20 日*
|
||
|
||
*請參閲本公告底部附註
|
||
|
||
價格資料
|
||
最終發售價 12.100 港元
|
||
發售價範圍 12.100 港元至 12.100 港元
|
||
進行發售價調整 否
|
||
|
||
發售股份及股本
|
||
發售股份數目 47,880,000
|
||
公開發售的發售股份數目(在重新分配後) 4,788,000
|
||
國際發售的發售股份數目(在重新分配後) 43,092,000
|
||
上市後已發行的股份數目 370,835,818
|
||
|
||
調整發售規模的選擇權
|
||
在發售規模調整選擇權下的額外股份數目 -
|
||
- 公開發售 -
|
||
- 國際發售 -
|
||
|
||
超額分配
|
||
超額分配的發售股份數目 -
|
||
|
||
所得款項
|
||
所得款項總額(附註) 579.35 百萬港元
|
||
減: 基於最終發售價的估計應付上市開支 (73.04)百萬港元
|
||
所得款項淨額 506.31 百萬港元
|
||
|
||
附註: 所得款項總額是指發行人有權收取的金額。有關所得款項用途的詳情，請參閱招股章程。
|
||
|
||
|
||
--- page 24 ---
|
||
配發結果詳情
|
||
|
||
香港公開發售
|
||
|
||
|
||
有效申請數目 974
|
||
受理申請數目 649
|
||
認購額 2.29倍
|
||
重新分配 無
|
||
香港公開發售項下初步可供認購的發售股份數目 4,788,000
|
||
自國際發售重新分配的發售股份數目 0
|
||
公開發售項下最終發售股份數目(在重新分配後) 4,788,000
|
||
香港公開發售項下發售股份數目佔全球發售的百分比 10.00%
|
||
|
||
附註 : 有 關 向 香港 公 開 發 售 進 行 最 終 股 份 分 配 的 詳 情 ， 投 資 者 可 以 參 考
|
||
www.eipo.com.hk/eIPOAllotment以名稱或標識號進行搜索，或者訪問 www.eipo.com.hk/eIPOAllotment
|
||
以獲取獲分配者的完整列表。
|
||
|
||
國際發售
|
||
|
||
|
||
承配人的數量 116
|
||
認購額 1.01倍
|
||
國際發售項下初步可供認購的發售股份數目 43,092,000
|
||
重新分配至香港公開發售的發售股份數目 0
|
||
國際發售項下最終發售股份數目(在重新分配後) 43,092,000
|
||
國際發售項下發售股份數目佔全球發售的百分比 90.00%
|
||
|
||
董事確認，據彼等所深知、盡悉及確信，及聯交所 就基石投資者長興興長（定義見下文）授出的豁免
|
||
及同意除外，(i)承配人及公眾人士認購的發售股份並非由本公司、任何董事、監事、本公司最高行政
|
||
人員、控股股東、主要股東、本公司現有股東或其任何附屬公司或彼等各自的緊密聯繫人直接或間接
|
||
撥資、且(ii)購買發售股份的承配人及公眾人士概無習慣受本公司、任何董事、監事、本公司最高行
|
||
政人員、控股股東、主要股東、本公司現有股東或其任何附屬公司或彼等各自的緊密聯繫人的指示而
|
||
對登記於其名下或其以其他方式持有的股份進行收購、出售、表決或其他處置。
|
||
|
||
|
||
國際發售中的承配人包括以下各項:
|
||
基石投資者
|
||
|
||
|
||
--- page 25 ---
|
||
投資者
|
||
|
||
獲分配的發售
|
||
股份數目
|
||
|
||
|
||
佔發售股份
|
||
的百分比
|
||
佔全球發售
|
||
後已發行
|
||
H股總數
|
||
的百分比
|
||
佔全球發售
|
||
後已發行
|
||
股本總額之
|
||
百分比
|
||
現有股東或
|
||
其緊密聯繫
|
||
人
|
||
長興興長產業
|
||
投資合夥企業
|
||
（有限合夥）
|
||
（「長興興
|
||
長」）
|
||
17,000,000 35.51% 8.83% 4.58% 是#
|
||
總計 17,000,000 35.51% 8.83% 4.58%
|
||
|
||
獲豁免╱同意的分配對象
|
||
|
||
|
||
|
||
投資者
|
||
獲分配
|
||
的股份
|
||
數目
|
||
|
||
佔發售股份
|
||
的百分比
|
||
佔全球發售
|
||
後已發行
|
||
H股總數
|
||
的百分比
|
||
佔全球發售
|
||
後已發行
|
||
股本總額之
|
||
百分比
|
||
|
||
|
||
關係*
|
||
|
||
長興興長
|
||
|
||
17,000,000
|
||
|
||
35.51%
|
||
|
||
8.83%
|
||
|
||
4.58%
|
||
|
||
核心關連人士
|
||
總計 17,000,000 35.51% 8.83% 4.58%
|
||
|
||
# 請參閱本公告「其他╱附加信息」一節。
|
||
|
||
*本公司已申請且聯交所已批准豁免嚴格遵守上市規則第 9.09(b)及 10.04 條。向長興興長分配發售
|
||
股份符合聯交所授予的所有條件。有關進一步詳情，請參閱招股章程「豁免嚴格遵守上市規則及
|
||
豁免嚴格遵守公司（清盤及雜項條文）條例」一節。
|
||
|
||
|
||
禁售承諾
|
||
控股股東
|
||
|
||
|
||
|
||
|
||
姓名╱名稱
|
||
上市後須遵守禁
|
||
售承諾的本公司
|
||
持股數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
上市後須遵守禁售
|
||
承諾
|
||
的本公司股權百分比
|
||
|
||
須遵守禁售
|
||
承諾的最後
|
||
一天
|
||
鄭州泰基鴻諾醫藥股
|
||
份有限公司（「泰基
|
||
鴻諾醫藥」）
|
||
附註1
|
||
100,000,000
|
||
（包括35,000,000
|
||
H股及65,000,000
|
||
非上市股份）
|
||
|
||
18.17%
|
||
|
||
26.97%
|
||
2025年8月19日
|
||
附註3
|
||
|
||
|
||
--- page 26 ---
|
||
長興利源企業管理
|
||
合夥企業（有限
|
||
合夥）（「長興利
|
||
源」）
|
||
附註2
|
||
22,670,000
|
||
（包括7,934,500
|
||
H股及14,735,500
|
||
非上市股份）
|
||
4.12% 6.11% 2025年8月19
|
||
日
|
||
附註3
|
||
長興罡源企業管理合
|
||
夥企業（有限合夥）
|
||
（「長興罡源」）
|
||
附註2
|
||
4,800,000
|
||
（包括1,680,000
|
||
H股及3,120,000非
|
||
上市股份）
|
||
0.87% 1.29% 2025年8月19
|
||
日
|
||
附註3
|
||
長興彩源企業管理合
|
||
夥企業（有限合夥）
|
||
（「長興彩源」）
|
||
附註2
|
||
3,780,000
|
||
（包括1,323,000
|
||
H股及2,457,000非
|
||
上市股份）
|
||
0.69% 1.02% 2025年8月19
|
||
日
|
||
附註3
|
||
小計 131,250,000 23.85% 35.39%
|
||
附註：
|
||
|
||
(1) 泰基鴻諾醫藥實益擁有35,000,000股H股及65,000,000股非上市股份。泰基鴻諾醫藥分別由吳
|
||
博士、鄭州鴻諾及鄭州德瑞持有約30.66%、20.15%及3.02%。鄭州鴻諾由其執行合夥人湖州
|
||
德瑞管理，而湖州德瑞由吳博士擁有38.75%，鄭州德瑞擁有61%及本集團僱員之一張森先生
|
||
擁有0.25%。鄭州德瑞由吳博士全資擁有。因此，根據證券及期貨條例，吳博士被視為於泰
|
||
基鴻諾醫藥持有的 35,000,000股H股及65,000,000股非上市股份中擁有權益。 Zhu女士為吳博
|
||
士的配偶。因此，根據證券及期貨條例， Zhu女士被視為於與吳博士擁有權益的相同股份數
|
||
目中擁有權益。
|
||
|
||
|
||
--- page 27 ---
|
||
(2) 長興利源實益擁有 7,934,500股H股及14,735,500股非上市股份。長興利源由其執行合夥人鄭
|
||
州德瑞（由吳博士全資擁有）管理。
|
||
|
||
長興彩源及長興罡源均為我們的員工持股計劃平台。長興彩源實益擁有 1,323,000股H股及
|
||
2,457,000股非上市股份。長興罡源實益擁有1,680,000股H股及3,120,000股非上市股份。長興
|
||
彩源及長興罡源各自由其執行合夥人湖州德瑞管理，而湖州德瑞由 吳博士擁有38.75%，鄭
|
||
州德瑞擁有61%及本集團僱員之一張森先生擁有0.25%。鄭州德瑞由吳博士全資擁有。
|
||
|
||
因 此 ， 根 據 證 券 及 期 貨 條 例 ， 吳 博 士 被 視 為 於(i) 長 興 利 源 持 有 的7,934,500 股 H 股及
|
||
14,735,500股非上市股份； (ii)長興彩源持有的 1,323,000股H股及2,457,000股非上市股份；及
|
||
(iii)長興罡源持有的1,680,000股H股及3,120,000股非上市股份中擁有權益。
|
||
|
||
(3) 以上表格所示禁售期屆滿日期乃依據香港包銷協議及適用的中國法律。
|
||
|
||
|
||
首次公開發售前投資者（按招股章程「歷史、發展及公司架構」一節中的定義）
|
||
|
||
|
||
|
||
|
||
|
||
姓名╱名稱
|
||
上市後須遵守禁
|
||
售承諾的本公司
|
||
持股數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
|
||
上市後須遵守禁售承
|
||
諾
|
||
的本公司股權百分比
|
||
|
||
|
||
須遵守禁售承
|
||
諾的最後一天
|
||
寧波梅山保稅港區厚紀
|
||
通諾投資管理合夥企業
|
||
（有限合夥）（厚紀通
|
||
諾）
|
||
附註1
|
||
14,146,619
|
||
（包括4,951,317H
|
||
股及9,195,302非
|
||
上市股份）
|
||
2.57% 3.81% 2025年8月19
|
||
日
|
||
附註7
|
||
長三角騰遠（長興）醫
|
||
療股權投資合夥企業
|
||
（有限合夥）（長三角
|
||
騰遠）
|
||
12,600,000
|
||
（包括4,410,000H
|
||
股及8,190,000非
|
||
上市股份）
|
||
2.29% 3.40% 2025年8月19
|
||
日
|
||
附註7
|
||
長興國海東湖股權投資
|
||
合夥企業（有限合夥）
|
||
（長興國海）
|
||
附註2及6
|
||
12,185,600
|
||
（包括3,046,400H
|
||
股及9,139,200非
|
||
上市股份）
|
||
1.58% 3.29% 2025年8月19
|
||
日
|
||
附註7
|
||
|
||
|
||
--- page 28 ---
|
||
姓名╱名稱
|
||
上市後須遵守禁
|
||
售承諾的本公司
|
||
持股數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
|
||
上市後須遵守禁售承
|
||
諾
|
||
的本公司股權百分比
|
||
|
||
|
||
須遵守禁售承
|
||
諾的最後一天
|
||
四川匯宇製藥股份有限
|
||
公司（匯宇製藥）
|
||
10,468,584
|
||
（包括3,664,004H
|
||
股及6,804,580非
|
||
上市股份）
|
||
1.90% 2.82% 2025年8月19
|
||
日
|
||
附註7
|
||
長興興銀股權投資合夥
|
||
企業（有限合夥）（長
|
||
興興銀）
|
||
附註3及6
|
||
10,015,305
|
||
（包括3,505,357H
|
||
股及6,509,948非
|
||
上市股份）
|
||
1.82% 2.70% 2025年8月19
|
||
日
|
||
附註7
|
||
江蘇毅達成果創新創業
|
||
投資基金（有限合夥）
|
||
（毅達成果）
|
||
附註4
|
||
9,600,000（H股） 4.98% 2.59% 2025年8月19
|
||
日
|
||
附註7
|
||
成都博遠嘉昱創業投資
|
||
合夥企業（有限合夥）
|
||
（成都博遠）
|
||
9,201,568
|
||
（包括3,220,549H
|
||
股及5,981,019股
|
||
非上市股份）
|
||
1.67% 2.48% 2025年8月19
|
||
日
|
||
附註7
|
||
江蘇中小企業發展基金
|
||
（有限合夥）（江蘇中
|
||
小企業）
|
||
附註4
|
||
7,200,000（H股） 3.74% 1.94% 2025年8月19
|
||
日
|
||
附註7
|
||
昆山華創毅達生醫
|
||
股權投資企業（有
|
||
限合夥）（華創毅
|
||
達）
|
||
7,200,000（H股） 3.74% 1.94% 2025年8月19
|
||
日
|
||
附註7
|
||
杭州三花弘道創
|
||
業投資合夥企業
|
||
（有限合夥）
|
||
（三花弘道）
|
||
7,200,000（H股） 3.74% 1.94% 2025年8月19
|
||
日
|
||
附註7
|
||
廈門融匯弘上股權投
|
||
資合夥企業（有限合
|
||
夥）（融匯弘上）
|
||
7,200,000
|
||
（包括2,520,000H
|
||
股及4,680,000非
|
||
上市股份）
|
||
1.31% 1.94% 2025年8月19
|
||
日
|
||
附註7
|
||
|
||
|
||
--- page 29 ---
|
||
姓名╱名稱
|
||
上市後須遵守禁
|
||
售承諾的本公司
|
||
持股數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
|
||
上市後須遵守禁售承
|
||
諾
|
||
的本公司股權百分比
|
||
|
||
|
||
須遵守禁售承
|
||
諾的最後一天
|
||
寧波複祺創業投資合夥
|
||
企業（有限合夥）（複
|
||
祺投資）
|
||
附註6
|
||
7,200,000
|
||
（包括2,520,000H
|
||
股及4,680,000非
|
||
上市股份）
|
||
1.31% 1.94% 2025年8月19
|
||
日
|
||
附註7
|
||
深圳揚子鑫康醫藥投資
|
||
企業（有限合夥）（揚
|
||
子鑫康）
|
||
6,259,566
|
||
（包括2,190,848H
|
||
股及4,068,17718
|
||
非上市股份）
|
||
1.14% 1.69% 2025年8月19
|
||
日
|
||
附註7
|
||
株洲市國海國創千金醫
|
||
藥創業投資合夥企業
|
||
（有限合夥）（國海國
|
||
創）
|
||
附註2
|
||
6,144,000
|
||
（包括1,536,000H
|
||
股及4,608,000非
|
||
上市股份）
|
||
0.80% 1.66% 2025年8月19
|
||
日
|
||
附註7
|
||
株洲市國創君和投資合
|
||
夥企業（有限合夥）
|
||
（國創君和）
|
||
附註5
|
||
5,400,000
|
||
（包括1,890,000H
|
||
股及3,510,000非
|
||
上市股份）
|
||
0.98% 1.46% 2025年8月19
|
||
日
|
||
附註7
|
||
寧波梅山保稅港區厚揚
|
||
通馳投資管理合夥企業
|
||
（有限合夥）（厚揚通
|
||
馳）
|
||
附註1
|
||
5,258,035
|
||
（包括1,840,312H
|
||
股及3,417,723非
|
||
上市股份）
|
||
0.96% 1.42% 2025年8月19
|
||
日
|
||
附註7
|
||
湖州中金啟合股權投資
|
||
合夥企業（有限合夥）
|
||
（中金啟合）
|
||
附註6
|
||
5,234,292（H股） 2.72% 1.41% 2025年8月19
|
||
日
|
||
附註7
|
||
株洲市文周君喆創業
|
||
投資合夥企業（有限
|
||
合夥）（文周君喆）
|
||
附註5
|
||
5,120,000
|
||
（包括1,792,000H
|
||
股及3,328,000非
|
||
上市股份）
|
||
0.93% 1.38% 2025年8月19
|
||
日
|
||
附註7
|
||
|
||
|
||
--- page 30 ---
|
||
姓名╱名稱
|
||
上市後須遵守禁
|
||
售承諾的本公司
|
||
持股數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
|
||
上市後須遵守禁售承
|
||
諾
|
||
的本公司股權百分比
|
||
|
||
|
||
須遵守禁售承
|
||
諾的最後一天
|
||
浙江絲路產業投資基
|
||
金合夥企業（有限合
|
||
夥）（浙江絲路）
|
||
5,007,653（H股） 2.60% 1.35% 2025年8月19
|
||
日
|
||
附註7
|
||
湖南湘醫投同源壹號
|
||
創業投資合夥企業
|
||
（有限合夥）（湖南
|
||
湘醫）
|
||
4,761,905
|
||
（包括1,666,667H
|
||
股及3,095,238非
|
||
上市股份）
|
||
0.87% 1.28% 2025年8月19
|
||
日
|
||
附註7
|
||
杭州啟真未來創新股
|
||
權投資合夥企業（有
|
||
限合夥）（杭州啟
|
||
真）
|
||
4,096,000（H股） 2.13% 1.10% 2025年8月19
|
||
日
|
||
附註7
|
||
揚州澤康股權投資合
|
||
夥企業（有限合夥）
|
||
（揚州澤康）
|
||
3,655,575
|
||
（包括1,279,451H
|
||
股及2,376,124非
|
||
上市股份）
|
||
0.66% 0.99% 2025年8月19
|
||
日
|
||
附註7
|
||
江蘇人才創新創業投
|
||
資四期基金（有限合
|
||
夥）（江蘇人才）
|
||
附註4
|
||
3,600,000（H股） 1.87% 0.97% 2025年8月19
|
||
日
|
||
附註7
|
||
長興鑫晟股權投資合
|
||
夥企業（有限合夥）
|
||
（長興鑫晟）
|
||
附註3及6
|
||
3,140,575
|
||
（包括1,099,201H
|
||
股及2,041,374非
|
||
上市股份）
|
||
0.57% 0.85% 2025年8月19
|
||
日
|
||
附註7
|
||
湖州海邦數湖創業投
|
||
資合夥企業（有限合
|
||
夥）（海邦數湖）
|
||
附註6
|
||
3,072,000
|
||
（包括1,075,200H
|
||
股及1,996,800非
|
||
上市股份）
|
||
0.56% 0.83% 2025年8月19
|
||
日
|
||
附註7
|
||
嘉興行仁股權投資合
|
||
夥企業（有限合夥）
|
||
（嘉興行仁）
|
||
2,380,952
|
||
（包括833,333H
|
||
股及1,547,619非
|
||
上市股份）
|
||
0.43% 0.64% 2025年8月19
|
||
日
|
||
附註7
|
||
|
||
|
||
--- page 31 ---
|
||
姓名╱名稱
|
||
上市後須遵守禁
|
||
售承諾的本公司
|
||
持股數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
|
||
上市後須遵守禁售承
|
||
諾
|
||
的本公司股權百分比
|
||
|
||
|
||
須遵守禁售承
|
||
諾的最後一天
|
||
吉愛寧先生 2,380,000
|
||
（包括833,000H
|
||
股及1,547,000非
|
||
上市股份）
|
||
0.43% 0.64% 2025年8月19
|
||
日
|
||
附註7
|
||
嘉興望盈上和股權投
|
||
資合夥企業（有限合
|
||
夥）（望盈上和）
|
||
附註6
|
||
1,884,160（H股） 0.98% 0.51% 2025年8月19
|
||
日
|
||
附註7
|
||
上海凱乘企業管理諮
|
||
詢合夥企業（有限合
|
||
夥）（上海凱乘）
|
||
720,000
|
||
（包括252,000H
|
||
股及468,000非上
|
||
市股份）
|
||
0.13% 0.19% 2025年8月19
|
||
日
|
||
附註7
|
||
上海凡熹企業管理合
|
||
夥企業（有限合夥）
|
||
（上海凡熹）
|
||
附註5
|
||
600,000
|
||
（包括210,000H
|
||
股及390,000非上
|
||
市股份）
|
||
0.11% 0.16% 2025年8月19
|
||
日
|
||
附註7
|
||
湖州市人才創新股權
|
||
投資基金合夥企業
|
||
（有限合夥）（湖州
|
||
人才）
|
||
附註6
|
||
523,429（H股） 0.27% 0.14% 2025年8月19
|
||
日
|
||
附註7
|
||
小計 183,455,818 49.79% 49.47%
|
||
附註：
|
||
(1) 厚紀通諾及厚揚通馳將合共持有19,404,654股股份，佔上市後本公司已發行股本總額約
|
||
5.23%。
|
||
(2) 長興國海及國海國創將合共持有18,329,600股股份，佔上市後本公司已發行股本總額約
|
||
4.94%。
|
||
(3) 長興興銀及長興鑫晟將合共持有13,155,880股股份，佔上市後本公司已發行股本總額約
|
||
3.55%。
|
||
(4) 毅達成果、江蘇中小企業及江蘇人才將合共持有20,400,000股股份，佔上市後本公司已發行股
|
||
本總額約5.50%。
|
||
(5) 國創君和、文周君喆及上海凡熹將合共持有11,120,000股股份，佔上市後本公司已發行股本總
|
||
額約3.00%。
|
||
(6) 相關股東合夥權益的30%以上最終由浙江省人民政府監督管理。誠如招股章程「基石配售」
|
||
一節進一步詳述，由浙江省人民政府監督管理的該等相關股東將合共持有43,255,361股股份，
|
||
|
||
|
||
--- page 32 ---
|
||
姓名╱名稱
|
||
上市後須遵守禁
|
||
售承諾的本公司
|
||
持股數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
|
||
上市後須遵守禁售承
|
||
諾
|
||
的本公司股權百分比
|
||
|
||
|
||
須遵守禁售承
|
||
諾的最後一天
|
||
佔上市後本公司已發行股本總額約11.66%（並無計及最終亦由浙江省人民政府監督管理的基
|
||
石投資者將予認購的股份）。
|
||
(7) 以上表格所示禁售期屆滿日期乃依據適用的中國法律。
|
||
|
||
現有股東（招股章程「歷史、發展及公司架構」一節中定義的首次公開發售前投資者除外）
|
||
|
||
|
||
|
||
|
||
|
||
|
||
姓名╱名稱
|
||
上市後須遵守禁售
|
||
承諾的本公司持股
|
||
數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
上市後須遵
|
||
守禁售承諾
|
||
的本公司股
|
||
權百分比
|
||
|
||
須遵守禁售
|
||
承諾的最後
|
||
一天
|
||
貝沃特醫藥技術（上
|
||
海）有限公司（貝沃特
|
||
醫藥）
|
||
8,250,000
|
||
（包括2,887,500H
|
||
股及5,362,500非
|
||
上市股份）
|
||
1.50% 2.22% 2025年8月19
|
||
日
|
||
小計 8,250,000 1.50% 2.22%
|
||
以上表格所示禁售期屆滿日期乃依據適用的中國法律。
|
||
|
||
基石投資者
|
||
|
||
|
||
|
||
|
||
|
||
姓名╱名稱
|
||
上市後須遵守禁售
|
||
承諾的本公司持股
|
||
數目
|
||
上市後須遵守禁售
|
||
承諾的全球發售後
|
||
全部已發行H股百分
|
||
比
|
||
上市後須遵守禁售
|
||
承諾的本公司股權
|
||
百分比
|
||
|
||
須遵守禁售
|
||
承諾的最後
|
||
一天
|
||
長興興長 17,000,000（H股
|
||
）
|
||
8.83% 4.58% 2025年2月19
|
||
日
|
||
小計 17,000,000 8.83% 4.58%
|
||
基石投資者不得於所示日期或之前出售根據基石投資協議認購的任何發售股份。
|
||
|
||
|
||
--- page 33 ---
|
||
配售人集中度分析
|
||
|
||
|
||
|
||
|
||
|
||
|
||
配售人(1)
|
||
|
||
|
||
|
||
|
||
獲配發H股數目
|
||
|
||
|
||
|
||
|
||
配發佔國際發售的百分比
|
||
|
||
|
||
|
||
|
||
配發佔發售股份總數的百
|
||
分比
|
||
|
||
|
||
|
||
上市後
|
||
所持股份數目(2)
|
||
|
||
|
||
|
||
|
||
佔上市後已發行股本總額的
|
||
百分比
|
||
最大 17,000,000 39.45% 35.51% 60,255,361 16.25%
|
||
前5 34,103,500 79.14% 71.23% 77,358,861 20.86%
|
||
前10 41,036,500 95.23% 85.71% 84,291,861 22.73%
|
||
前25 43,046,500 99.89% 89.90% 86,301,861 23.27%
|
||
|
||
附註
|
||
(1) 配售人排名基於配發給配售人的H股數量。
|
||
(2) 上市後所持股份數目包括現有股份。
|
||
|
||
|
||
--- page 34 ---
|
||
H股股東股權集中度分析
|
||
|
||
|
||
|
||
|
||
|
||
H股股東(1)
|
||
|
||
|
||
獲配發H股數目
|
||
|
||
|
||
配發佔國際
|
||
發售的百分比
|
||
|
||
|
||
配發佔發售股份總
|
||
數的百分比
|
||
|
||
|
||
上市後所持H股數目
|
||
|
||
|
||
佔上市後已發行H股
|
||
總數的百分比
|
||
|
||
|
||
|
||
上市後所持股份數目(2)
|
||
最大 0 0.00% 0.00% 45,937,500 23.85% 131,250,000
|
||
前5 17,000,000 39.45% 35.51% 116,625,539 60.56% 226,305,361
|
||
前10 29,113,500 67.56% 60.81% 144,948,321 75.26% 275,431,168
|
||
前25 39,406,500 91.45% 82.30% 182,194,340 94.60% 356,881,366
|
||
|
||
附註：
|
||
(1) H股股東排名基於H股股東在上市後所持的H股數量。
|
||
(2) 上市後所持股份數目包括現有股份。
|
||
|
||
|
||
--- page 35 ---
|
||
股權集中度分析
|
||
|
||
|
||
|
||
|
||
|
||
股東(1)
|
||
|
||
|
||
|
||
|
||
獲配發H股數目
|
||
|
||
|
||
|
||
|
||
配發佔國際發售的百分比
|
||
|
||
|
||
|
||
|
||
配發佔發售股份總數的百
|
||
分比
|
||
|
||
|
||
|
||
|
||
上市後所持股份數目(2)
|
||
|
||
|
||
|
||
佔上市後已發行股本總額
|
||
的百分比
|
||
最大 0 0.00% 0.00% 131,250,000 35.39%
|
||
前5 17,000,000 39.45% 35.51% 243,910,015 65.77%
|
||
前10 17,000,000 39.45% 35.51% 290,150,167 78.24%
|
||
前25 36,543,500 84.80% 76.32% 358,779,318 96.75%
|
||
|
||
附註
|
||
(1) 股東排名基於股東在上市後所持的（所有類別）股份數量。
|
||
(2) 上市後所持股份數目包括現有股份。
|
||
|
||
|
||
--- page 36 ---
|
||
香港公開發售的分配準則
|
||
招股章程所載的條件獲達成後， 公眾提出的974份有效申請將按下列準 則有條件分配：
|
||
甲組：
|
||
|
||
所申請
|
||
H 股數目
|
||
|
||
有效申
|
||
請數目
|
||
|
||
|
||
配發╱抽
|
||
籤基準
|
||
|
||
獲配發 H
|
||
股佔所申請總數的
|
||
概約百分比
|
||
|
||
500
|
||
|
||
614 614 名中 294 名獲發 500
|
||
股股份
|
||
|
||
47.88%
|
||
|
||
|
||
1,000
|
||
|
||
117 117 名中 112 名獲發 500
|
||
股股份
|
||
|
||
47.86%
|
||
|
||
|
||
1,500
|
||
|
||
37 500 股股份加上 37 名中 16 名
|
||
獲發額外 500 股股份
|
||
|
||
47.75%
|
||
|
||
|
||
2,000
|
||
|
||
36 500 股股份加上 36 名中 32 名
|
||
獲發額外 500 股股份
|
||
|
||
47.22%
|
||
|
||
2,500
|
||
|
||
18 1,000 股股份加上 18 名中 6 名
|
||
獲發額外 500 股股份
|
||
|
||
46.67%
|
||
|
||
|
||
3,000
|
||
|
||
19 1,000 股股份加上 19 名中 15
|
||
名獲發額外 500 股股份
|
||
|
||
46.49%
|
||
|
||
|
||
3,500
|
||
|
||
8 1,500 股股份加上 8 名中 2 名
|
||
獲發額外 500 股股份
|
||
|
||
46.43%
|
||
|
||
|
||
4,000
|
||
|
||
20 1,500 股股份加上 20 名中 14
|
||
名獲發額外 500 股股份
|
||
|
||
46.25%
|
||
|
||
|
||
4,500
|
||
|
||
1
|
||
|
||
2,000 股股份
|
||
|
||
44.44%
|
||
|
||
|
||
5,000
|
||
|
||
23 2,000 股股份加上 23 名中 10 名
|
||
獲發額外 500 股股份
|
||
|
||
44.35%
|
||
|
||
|
||
6,000
|
||
|
||
5 2,500 股股份加上 5 名中 1 名
|
||
獲發額外 500 股股份
|
||
|
||
43.33%
|
||
|
||
|
||
7,000
|
||
|
||
2
|
||
|
||
3,000 股股份
|
||
|
||
42.86%
|
||
|
||
8,000
|
||
|
||
7
|
||
|
||
3,000 股股份加上 7 名中 5 名
|
||
獲發額外 500 股股份
|
||
|
||
41.96%
|
||
|
||
|
||
9,000
|
||
|
||
7 3,500 股股份加上 7 名中 2 名
|
||
獲發額外 500 股股份
|
||
|
||
40.48%
|
||
|
||
|
||
10,000
|
||
|
||
18
|
||
|
||
4,000 股股份
|
||
|
||
40.00%
|
||
|
||
15,000
|
||
|
||
3
|
||
|
||
6,000 股股份
|
||
|
||
40.00%
|
||
|
||
|
||
--- page 37 ---
|
||
所申請
|
||
H 股數目
|
||
|
||
有效申
|
||
請數目
|
||
|
||
|
||
配發╱抽
|
||
籤基準
|
||
|
||
獲配發 H
|
||
股佔所申請總數的
|
||
概約百分比
|
||
|
||
|
||
20,000
|
||
|
||
5
|
||
|
||
8,000 股股份
|
||
|
||
40.00%
|
||
|
||
|
||
25,000
|
||
|
||
3
|
||
|
||
10,000 股股份
|
||
|
||
40.00%
|
||
|
||
|
||
30,000
|
||
|
||
3
|
||
|
||
12,000 股股份
|
||
|
||
40.00%
|
||
50,000
|
||
3
|
||
|
||
20,000 股股份
|
||
|
||
40.00%
|
||
60,000
|
||
1
|
||
|
||
24,000 股股份
|
||
|
||
40.00%
|
||
70,000
|
||
1
|
||
|
||
28,000 股股份
|
||
|
||
40.00%
|
||
80,000
|
||
1
|
||
|
||
31,500 股股份
|
||
|
||
39.38%
|
||
90,000
|
||
1
|
||
|
||
35,000 股股份
|
||
|
||
38.89%
|
||
100,000
|
||
5
|
||
|
||
38,500 股股份
|
||
|
||
38.50%
|
||
200,000
|
||
4 76,500 股股份加上 4 名中 3 名
|
||
獲發額外 500 股股份
|
||
|
||
38.44%
|
||
300,000
|
||
5 115,000 股股份加上 5 名中 3 名
|
||
獲發額外 500 股股份
|
||
|
||
38.43%
|
||
400,000
|
||
3 153,500 股股份加上 3 名中 1 名
|
||
獲發額外 500 股股份
|
||
|
||
38.42%
|
||
總計 970 甲組獲接納申請人總數：645
|
||
|
||
|
||
--- page 38 ---
|
||
乙組
|
||
|
||
所申請
|
||
H 股數目
|
||
|
||
有效申
|
||
請數目
|
||
|
||
|
||
配發╱抽
|
||
籤基準
|
||
|
||
獲配發 H
|
||
股佔所申請總數的
|
||
概約百分比
|
||
500,000 1 240,000 股股份 48.00%
|
||
1,250,000 1 598,500 股股份 47.88%
|
||
1,500,000 1 718,000 股股份 47.87%
|
||
1,750,000 1 837,500 股股份 47.86%
|
||
總計
|
||
|
||
4 乙組獲接納申請人總數：4
|
||
|
||
|
||
截至本公告日期，此前存放於指定代理人戶口的相關認購款項已匯回至所有香港結算參與
|
||
者的賬戶。投資者如有任何查詢，請聯絡其相關經紀。
|
||
|
||
遵守上市規則和指引
|
||
董事確認，除上市規則已獲豁免及 ╱或已取得同意外，本公司已遵守有關 H股配售、配發
|
||
及上市的上市規則及指引。
|
||
董事確認，就彼等所知，除任何經紀佣金、會財局交易徵費、證監會交易徵費及應付交易費
|
||
外，配售人或公眾人士（視情況而定）直接或間接就彼等認購或購買的每股發售股份支付的
|
||
代價與最終發售價相同。
|
||
|
||
其他╱附加信息
|
||
|
||
本公司已向聯交所申請，且聯交所已向本公司授出豁免及上市規則第 9.09(b)條及第 10.04 條
|
||
規定及配售指引第 5(2)段的同意，允許長興興長作為基石投資者在全球發售中認購 H 股。由
|
||
於湖州人才、長興興銀、長興鑫晟、中金啟合、長興國海、海邦數湖、望盈上和及複祺投資
|
||
（現有股東，統稱「浙江相關實體」）各自合夥權益的 30%以上最終由浙江省人民政府監督
|
||
管理，且浙江相關實體於上市後將合計持有 43,255,361 股股份（即本公司已發行股本總額的
|
||
約 11.66%），故被視為本公司的核心關連人士。長興興長為一家由長興縣人民政府（為浙江
|
||
省的一個縣政府）監督管理的實體。 有關詳情，請參閱「豁免嚴格遵守上市規則及豁免嚴格
|
||
遵守公司（清盤及雜項條文）條例－核心關連人士在上市申請過程中進行基石認購」一節。
|
||
|
||
|
||
--- page 39 ---
|
||
免責聲明
|
||
|
||
|
||
香港交易及結算所有限公司、香港聯合交易所有限公司（「 聯交所 」）及香港中央結算有
|
||
限公司（「 香港結算 」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲
|
||
明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任
|
||
何損失承擔任何責任。
|
||
本公告不會直接或間接於或向美國（包括美國的領土及屬地、任何州以及哥倫比亞特區）發
|
||
佈、 刊發、分發。本公告並不構成或組成在美國購買或認購證券的任何要約或招攬的一部
|
||
分。本公告所述證券並無亦不會根據1933年美國證券法（經修訂）（「美國證券法」）登
|
||
記。除非證券已獲豁免美國證券法的登記規定並符合任何適用州證券法，否則不得在美國提
|
||
呈發售或 出售；或除非符合美國證券法S規例，否則不得在美國境外提呈發售或出售。證券將
|
||
不會在美國公開發售。
|
||
發售股份根據美國證券法S規例以離岸交易方式在美國境外提呈發售及出售。
|
||
本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。 潛
|
||
在投資者在決定是否投資 所提呈發售股份前，務請細閱 浙江同源康醫藥股份有限公司所刊發
|
||
日期為2024年8月12日的招股章程，以了解下文所述有關全球發售的詳細資料。
|
||
發售股份的潛在投資者務請注意，整體協調人（為其本身及代表香港包銷商）有權在招股章
|
||
程「包銷－2.包銷安排及開支－香港公開發售－終止理由」一段所載的任何事件發生後，於上
|
||
市日期（目前預期為2024年8月20日）上午八時正（香港時間）之前隨時即時終止彼等於香港
|
||
包銷協議項下的責任。
|
||
|
||
公眾持股量
|
||
緊 隨 全 球 發 售 完 成 後 ，(i)經 計 及 首 次 公 開 發 售 前 投 資 者 及 現 有 股 東 將 獲 發 行 及 持 有 的
|
||
144,706,173股從未上市股份轉換的 H股，93,007,501股H股（佔已發行股份總數的 25.08%）將
|
||
由公眾持有，符合上市規則第 8.08(1)條項下的最低百分比規定； (ii)根據上市規則第8.08(3)及
|
||
8.24條，上市時由公眾人士持有的股份中，由持股量最高的三名公眾股東擁有的百分比，不
|
||
會超過50%；及(iii)根據上市規則第8.08(2)條，於上市時股東人數將至少為300人。
|
||
董事確認，緊隨全球發售完成後， (i)概無配售人可單獨獲配售本公司經擴大已發行股本之
|
||
10%以上；及(ii)本公司將不會有任何新主要股東（定義見上市規則）。
|
||
開始買賣
|
||
僅於全球發售已成為無條件且「包銷－ 2.包銷安排及開支－香港公開發售－終止理由」所述
|
||
終止權利未獲行使的情況下， H股股票方會於2024年8月20日（星期二）上午八時正（香港時
|
||
間）成為有效所有權憑證。倘投資者在獲發H股股票前或在H股股票成為有效的所有權憑證前
|
||
按照公開的分配詳情買賣股份，須自行承擔一切風險。
|
||
|
||
假設香港公開發售於2024年8月20日（星期二）上午八時正（香港時間）或之前成為無條件，
|
||
則預期H股將於2024年8月20日（星期二）上午九時正（香港時間）開始在聯交所買賣。 H股
|
||
|
||
|
||
--- page 40 ---
|
||
將以每手500股H股進行買賣，H股的股份代號將為2410。
|
||
|
||
承董事會命
|
||
浙江同源康醫藥股份有限公司
|
||
董事長、執行董事兼總裁
|
||
吳豫生博士
|
||
|
||
|
||
香港，2024年8月19日
|
||
|
||
截至本公告日期，執行董事為吳豫生博士及蔣鳴昱博士，非執行董事為李鈞博士、顧虹博士、
|
||
孟曉英博士、何超先生及丁兆博士，獨立非執行董事為張森泉先生、冷瑜婷博士、許文青博
|
||
士及沈秀華博士。
|